L.M. and M.A.F. contributed equally to the work.
Introduction
Single-centre experience suggests that patients with minimal lymph node (LN) disease (defined as only one or two LN metastases at radical prostatectomy [RP] and pelvic LN dissection [PLND]) may not progress for up to 15 years if these LNs are removed, even without adjuvant therapy [1] [2] [3] [4] [5] . These results would not seem possible if metastatic LNs had been left in, suggesting that for these patients each positive LN should be found and removed.
In 2008, our lymphoscintigraphic study documented that there were also primary landing sites along the common iliac vessels at least up to the ureter crossing, in the fossa of Marcille, and occasionally in the para-aortic/paracaval regions up to the inferior mesenteric artery [6] . Along the internal iliac vessels, primary landing sites were also found medially to the vessels. That study suggested that the frequently cited description of first, second and third echelon of LNs does not reflect progressive stages. Rather, the radioactive tracer was found at the level of the three echelons simultaneously after intraprostatic injection.
Consequently, we expanded our field of PLND beyond that of the classic extended template, including the common iliac region up to the ureter crossing and the fossa of Marcille bilaterally. It remained to be seen, however, whether solitary LN metastasis or minimal LN disease could indeed be found outside the classic extended template. If true, then the use of a more extended field might be justified, especially if risk of complications was not significantly increased.
Patients and Methods

Patients
After obtaining Ethics Committee approval, we reviewed prospectively collected data on 850 consecutive patients with localized prostate cancer who underwent RP between January 2000 and August 2015 at our institution. All patients had negative staging studies including CT or MRI of the abdomen and pelvis and bone scan scintigraphy. We excluded patients who received preoperative hormonal or radiation therapy (n = 5) and those who did not undergo PLND (n = 29). Patients operated on in 2009 (n = 63) were not included, as the new template was gradually introduced and both templates were in use during that year. The final cohort consisted of 753 patients, of whom 485 (64%) underwent RP and PLND between 2000 and 2008 (historical cohort), and 268 (36%) between 2010 and 2015 (contemporary cohort).
Templates for PLND and Surgical Technique
The RP technique used has been described previously [7] . Every patient received an extended PLND once the indication for RP was given. In the period 2000-2008, the template (Fig. 1A) included LNs located along the external iliac vein up to the common iliac bifurcation as well as those in the obturator fossa and along the internal iliac artery. From 2010, the template (Fig. 1B) additionally included LNs located up to the mid-common iliac region where the ureter crosses the iliac vessels, as well as those located dorsolateral to the external iliac vessels and the bifurcation of the common iliac vessels, in the fossa of Marcille (Fig. 2) , and on the medial aspect of the internal iliac vessels. Every RP and PLND was supervised by one of three senior surgeons.
Pathology
During the entire study period, LNs were submitted separately by drainage region for right and left side as external iliac (including the obturator fossa) and internal iliac, and, regularly from 2010 onwards, as common iliac and fossa of Marcille. Lymphadenectomy specimens were fixed in neutral buffered 4% formaldehyde and inspected grossly for LNs by palpation and sectioning. LNs >5 mm were sliced in thicknesses of 2-4 mm. After paraffin embedding, haematoxylin and eosin staining was performed on one slide from every block. RP specimens were processed as previously described [8] . Primary tumour and LNs were staged according to the 2010 edition of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system [9] .
Complications
Because a major objective of the present analysis was to determine whether extending the PLND template led to more complications, we focused on complications potentially associated with PLND within 30 and 90 days, and purposely did not report the full spectrum of complications after RP. These PLND-related complications were graded according to the modified Clavien-Dindo system [10] and included: lymphoceles/lymphoedemas; ureter injuries/strictures; neuropraxias; and thromboembolic events. In addition, although bleeding during RP most often results from the RP itself, notably during transection of Santorini's plexus, we 
Functional Outcomes
Information on continence and potency was prospectively recorded from follow-up appointments and mail or telephone correspondence, using a previously published standardized questionnaire [7, 11] . Urinary continence was defined as no pad use or occasional light pad use for security reasons. All patients were continent prior to RP. Potency was defined as patient self-report of the ability to achieve erection sufficient for penetration and maintenance of intercourse, with or without medical assistance. Patients who, prior to RP, reported absence of erection sufficient for penetration or who did not receive some form of nerve-sparing were excluded from the potency evaluation (n = 121).
Statistical Analyses
Comparisons of baseline characteristics, pathological features, complications and functional outcomes between the historical cohort and the contemporary cohort were assessed using the chi-squared test or Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables. A logistic regression model tested whether PLND template was an independent predictor of LN metastasis, adjusting for age (continuous), baseline PSA (continuous), tumour stage (pT2 vs pT3-T4), and Gleason score (<7, 7 and >7). A similar model was constructed to evaluate the risk of biochemical recurrence within 3 years, defined as PSA ≥0.2 ng/mL in two consecutive measurements. Finally, sub-analysis of patients with ≤2 LN metastases was performed because these patients may be the ones who would most benefit from removal of LN metastases [1] [2] [3] [4] [5] . Calculations were performed using IBM SPSS 23 (IBM, Armonk, NY, USA). All tests were two-sided, with P values <0.05 taken to indicate statistical significance.
Results
There was no difference in baseline PSA levels between the historical and contemporary cohorts (Table 1) ; however, patients in the contemporary cohort were more likely to have pT3-T4 disease (P < 0.001) and were more likely to have LN metastases. In the historical cohort, 80 patients (16% (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) in the historical cohort and 34 (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) in the contemporary cohort (P < 0.001). In the contemporary cohort, the median (IQR) number of LNs removed in the common iliac regions was 4 (2-6) and 4.5 (3-7) in the fossa of Marcille.
Among the 80 patients with pN+ disease in the historical cohort, the location of metastases on one or both sides was external iliac/obturator fossa in 23/80 (29%) and internal iliac in 18/80 (23%); the other 39 patients (49%) had metastases in both locations. More of the 266 LN metastases were found in the external iliac/obturator fossa regions (154; 58%) than in the internal iliac (112; 42% [ Table 1 ]).
Among the 72 patients with pN+ disease in the contemporary cohort, the location of metastases on one or both sides was external iliac/obturator fossa in 17/72 (24%), internal iliac in 24/72 (33%), and common iliac in 1/72 (1%); the other 30 patients (42%) had metastases in more than one location. A total of 12 patients had metastases in the common iliac regions alone or along with other locations. Although five patients (7%) had LN metastases in the fossa of Marcille, that was not the exclusive location in any case. Thus, we identified one patient with pN+ disease in the contemporary cohort who would have been classified as pN0 using the old template; however, because all internal iliac LNs were submitted as one region, we were unable to determine how many patients had LN metastases on the medial aspect of the internal iliac vessels only. Distribution of the 234 LN metastases was evenly divided between the external iliac/ obturator fossa (100; 43%) and internal iliac regions (102; 44%), yet with a substantial number found in the common iliac regions (23; 10%) and fossae of Marcille (9; 4%).
Multivariable analysis showed no significant difference in the probability of detecting LN metastases using the moreextended template compared with the classic extended template (nonsignificant 19% higher probability in the contemporary cohort [odds ratio 1.19, 95% CI 0.77-1.84; P = 0.4]; Table 2 ). As expected, the probability of detecting LN metastases was greater with higher PSA level, pathological classification, or Gleason score (Table 2 ). In addition, patients in the contemporary cohort had a higher risk of biochemical recurrence within 3 years (Table S1 ).
The historical cohort had fewer patients with minimal LN disease (≤2 metastases): 52/485 (11%) vs 46/268 (17%) in the contemporary cohort (P = 0.01). In these 98 patients with minimal LN disease, the metastases were in the external iliac/ obturator regions only in 37/98 patients (38%), in the internal iliac regions only in 38/98 patients (39%), or in both regions in 20/98 patients (20%). In the contemporary cohort, of all patients with minimal LN disease, three had one or both metastases in the common iliac regions or the fossae of Marcille.
Looking at complications potentially associated with PLND, there was no significant difference in numbers of lymphoceles/lymphoedemas, ureteric injuries/strictures, 
Discussion
Because there may be oncological benefit for patients with low-volume nodal disease or negative LNs [1] [2] [3] [4] [5] [12] [13] [14] [15] , our institution uses an extended PLND whenever RP is indicated.
In the present study, we show that by extending our template to the ureter crossing and including the fossa of Marcille, LN metastases can be identified in these new regions either in the context of minimal LN disease (≤2 LN metastases) or in conjunction with multiple LNs in other locations.
These findings support our LN mapping studies [6, 16] , speaking against the echelon theory that postulates that metastases do not occur in LNs of the second (common iliac vessels) or third echelon (paraaortal/paracaval) as long as the first echelon (areas caudal to the common iliac bifurcation) is free of tumour. In addition, over a century ago Cun eo and Marcille described three main paths draining the prostate [17] : lymphatics stretched along the external iliac vessels, internal iliac vessels and common iliac vessels. The medial chain of the common iliac LNs receiving direct afferents from the prostate was named 'groupe du promontoire' (nowadays generally called presacral nodes). Posterior common iliac LNs were located in the eponymous lumbosacral fossa: the fossa of Marcille was anatomically defined as the region dorsolateral to the proximal external iliac vessels and the bifurcation of the common iliac vessels. A third subgroup of common iliac LNs was found laterally.
The pioneering work of Cun eo and Marcille has been confirmed by several groups performing lymphoscintigraphic studies based on the sentinel LN concept [6, 18, 19] . In our 2008 mapping study, the locations of primary lymphatic landing sites were external iliac/obturator fossa in 38%, internal iliac in 25%, presacral/pararectal in 8%, common iliac in 16%, and paraaortic/caval in 12% [6] . Only 63% of the lymphatic landing sites were located inside the boundaries of a PLND limited cranially by the bifurcation of the common iliac artery. By extending the dissection along common iliac vessels up to the ureter crossing, approximately 75% of all LNs potentially harbouring metastases would have been removed. Thus, from 2009 onwards, we extended the PLND template accordingly, stretching the cranial boundary up to the crossing of the ureter, and including the fossa of Marcille.
As mentioned previously, we almost always perform PLND whenever the indication for RP is given. We do not base the decision of PLND on preoperative characteristics because the latter do not accurately predict the probability of finding positive nodes in an individual patient. For example, in our contemporary cohort there were 59 patients with biopsy Gleason score 6. A total of 40 patients were upgraded on final pathology, of which five were found to have LN metastases.
As expected from previous studies [20] [21] [22] , extending our PLND template resulted in more LNs removed (median 34 vs 23 with the less-extended template). It has been previously documented that removal of a greater number of LNs at RP is associated with a linear increase in the probability of detecting LN invasion [13, 23] . Heidenreich et al. [20] found twice as many positive LNs using the extended vs the limited template (26% vs 12%; P < 0.03). We found a 19% higher probability of detecting LN metastases with the new template; 26 (5) 23 (9) 29 (6) 30 (11) Grade 3b 7 (1) 4 (1) 10 (2) 7 (3) Lymphoceles/lymphoedema, n (%) 36 (7) 27 (10) 0.2* 41 (8) 33 (12) 0.1* Ureter injury/stricture, n (%) 0 A key question that remains is whether a more extended PLND benefits the patient in the long term. As we were comparing two cohorts with different follow-up times, it was futile to attempt comprehensive analysis of survival outcomes. Our biochemical recurrence data are probably misleading given the confounding related to discrepancies in patient characteristics, which cannot be fully removed by multivariable analysis. In addition, there are certainly important differences in unmeasured, competing variables that are not accounted for in the model. The current body of literature, however, provides some interesting insights [1] [2] [3] [4] [5] 24] . One large single-centre study recently showed that the removal of more LNs in node-positive patients who underwent extended PLND was associated with improvement in cancer-specific survival [24] . We identified one patient with pN+ disease in the contemporary cohort who would have been classified as pN0 using the old template. Unfortunately, we were unable to determine how many patients had LN metastases on the medial aspect of the internal iliac vessels only; thus, it is possible that additional patients with pN+ disease in the contemporary cohort would have been misclassified using the old template. However, it is more interesting to analyse patients who have minimal LN disease, including in these new areas. Those patients may be the ones who benefit most from a more extended PLND. We showed previously that cancer-specific survival probability at 10 years for patients with 1, 2 and ≥3 positive LNs was 72%, 79% and 33%, respectively [1] . Touijer et al. [2] documented that patients with ≥3 positive LNs at RP had a significantly higher risk of biochemical recurrence compared with patients with low-volume LN disease. In our contemporary cohort, a significantly higher proportion of patients had 1-2 LN metastases only (17% vs 11% in the historical cohort). Lastly, there is also evidence suggesting that the extent of PLND is associated with improved survival in patients with pN0 disease [12] [13] [14] [15] , possibly through the removal of micrometastases that are not detected by routine pathological processing. Indeed, up to 30% of histologically classified patients with pN0 disease were found to harbour micrometastases when molecular techniques were used [25] . Thus, from the literature the hypothesis that a more extended PLND is associated with survival benefit can be suggested, though not fully supported.
Complications potentially associated with PLND did not significantly differ between the two cohorts. This may be attributable to our meticulous technique, which includes ligation instead of clipping of lymphatics from the lower extremities and placement of bilateral wound drains.
Nevertheless, the study may be subject to uncaptured complications because of its retrospective nature. A prospective analysis is needed to confirm the lack of differences in complications between the two templates. Finally, the new template did not lead to worse functional outcomes in terms of continence and potency, which is probably explained by the fact that the medial boundary of our template is still outlined laterally to the autonomic nerves [26] . The potency data, however, should be interpreted carefully as the contemporary cohort probably benefited from more intense penile rehabilitation programmes.
Because of its retrospective nature, the present study is subject to potential limitations such as uncaptured complications and variable surgical experience among different surgeons; however, PLND was performed in a standardized, single-centre setting with high consistency in surgical philosophy and technique. Although LN specimen processing was consistent throughout the study period, no central pathology review was performed. Although a standardized pathology protocol was applied [8] , a heterogeneous nodal count cannot be excluded with certainty. Another limitation is the use of institutional questionnaires pre-and postoperatively instead of validated instruments for functional outcomes, such as the Sexual Health Inventory for Men score. In addition, the relatively small sample size of the contemporary cohort may explain the lack of predictive value of the new template to detect LN metastases. These limitations notwithstanding, the study highlights the fact that a more extended PLND may detect more patients with minimal LN disease. It may also provide better staging of patients; however, while we identified only one patient with pN+ disease in the contemporary cohort who would have been classified as pN0 using the old template, the patient sample was relatively small and we could not determine the number of patients with LN metastases on the medial aspect of the internal iliac vessels only. These data pave the way for a timely discussion on the topic of PLND given the current paradigm change in the management of patients with prostate cancer, with the trend towards recommending active surveillance to low-risk patients and treating only high-risk patients who have a higher risk of LN metastasis.
In conclusion, stretching the boundaries of the extended PLND template led to the detection of LN metastases in the common iliac regions and in the fossa of Marcille. The overall probability of detecting LN metastases with the new template, however, was not significantly higher. Furthermore, the new template was not associated with a higher risk of complications.
